ARROWHEAD PHARMACEUTICALS IN's ticker is ARWR and the CUSIP is 04280A100. A total of 315 filers reported holding ARROWHEAD PHARMACEUTICALS IN in Q4 2020. The put-call ratio across all filers is 0.54 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $22,704,747 | -44.4% | 844,985 | -26.2% | 0.01% | -41.7% |
| Q2 2023 | $40,832,804 | +38.9% | 1,145,059 | -1.1% | 0.01% | +33.3% |
| Q1 2023 | $29,402,405 | -36.3% | 1,157,575 | +1.7% | 0.01% | -40.0% |
| Q4 2022 | $46,175,248 | +26.6% | 1,138,443 | +3.1% | 0.02% | +15.4% |
| Q3 2022 | $36,486,000 | -4.0% | 1,103,943 | +2.3% | 0.01% | 0.0% |
| Q2 2022 | $37,988,000 | -23.9% | 1,078,888 | -0.6% | 0.01% | -13.3% |
| Q1 2022 | $49,933,000 | -28.3% | 1,085,723 | +3.4% | 0.02% | -28.6% |
| Q4 2021 | $69,608,000 | +8.2% | 1,049,894 | +1.9% | 0.02% | 0.0% |
| Q3 2021 | $64,350,000 | -22.8% | 1,030,753 | +2.4% | 0.02% | -25.0% |
| Q2 2021 | $83,371,000 | +30.9% | 1,006,645 | +4.8% | 0.03% | +21.7% |
| Q1 2021 | $63,681,000 | -10.5% | 960,347 | +3.5% | 0.02% | -17.9% |
| Q4 2020 | $71,167,000 | +80.7% | 927,495 | +1.4% | 0.03% | +55.6% |
| Q3 2020 | $39,388,000 | +25.0% | 914,717 | +25.4% | 0.02% | +20.0% |
| Q2 2020 | $31,508,000 | +55.8% | 729,508 | +3.8% | 0.02% | +25.0% |
| Q1 2020 | $20,227,000 | -49.3% | 703,026 | +11.8% | 0.01% | -42.9% |
| Q4 2019 | $39,902,000 | +134.3% | 629,061 | +4.1% | 0.02% | +110.0% |
| Q3 2019 | $17,031,000 | +7.9% | 604,362 | +1.5% | 0.01% | 0.0% |
| Q2 2019 | $15,783,000 | +38.1% | 595,553 | -4.4% | 0.01% | +42.9% |
| Q1 2019 | $11,431,000 | +91.0% | 622,924 | +29.3% | 0.01% | +40.0% |
| Q4 2018 | $5,984,000 | -35.1% | 481,743 | +0.1% | 0.01% | -16.7% |
| Q3 2018 | $9,223,000 | +48.1% | 481,066 | +5.1% | 0.01% | +20.0% |
| Q2 2018 | $6,228,000 | +216.3% | 457,891 | +67.7% | 0.01% | +150.0% |
| Q1 2018 | $1,969,000 | +187.0% | 273,042 | +46.5% | 0.00% | +100.0% |
| Q4 2017 | $686,000 | -7.5% | 186,381 | +8.8% | 0.00% | 0.0% |
| Q3 2017 | $742,000 | +194.4% | 171,249 | +10.4% | 0.00% | – |
| Q2 2017 | $252,000 | -17.9% | 155,146 | -6.5% | 0.00% | – |
| Q1 2017 | $307,000 | -28.4% | 165,878 | -40.0% | 0.00% | – |
| Q4 2016 | $429,000 | -78.5% | 276,619 | +2.0% | 0.00% | -100.0% |
| Q3 2016 | $1,993,000 | +243.0% | 271,118 | +148.5% | 0.00% | +100.0% |
| Q2 2016 | $581,000 | – | 109,100 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| WESTERN FINANCIAL Corp | 820,264 | $54,392,000 | 33.22% |
| Johnson & Johnson Innovation - JJDC, Inc. | 3,260,869 | $216,228,000 | 28.00% |
| L1 Capital Pty Ltd | 296,024 | $19,629,000 | 4.93% |
| Aquilo Capital Management, LLC | 407,926 | $27,050,000 | 4.89% |
| Evolutionary Tree Capital Management, LLC | 72,948 | $4,837,000 | 2.86% |
| ACUTA CAPITAL PARTNERS, LLC | 108,000 | $7,161,000 | 2.58% |
| First Light Asset Management, LLC | 536,836 | $35,598,000 | 2.36% |
| Parkman Healthcare Partners LLC | 70,089 | $4,648,000 | 1.08% |
| Hood River Capital Management LLC | 357,082 | $23,678,000 | 0.76% |
| Vanguard Capital Wealth Advisors | 11,099 | $703,565,000 | 0.60% |